DAFTAR PUSTAKA. 1. Stewart SL Ovarian Cancer Incidence: Current and Comprehensive Statistics.

Save this PDF as:
Size: px
Start display at page:

Download "DAFTAR PUSTAKA. 1. Stewart SL Ovarian Cancer Incidence: Current and Comprehensive Statistics."


1 DAFTAR PUSTAKA 1. Stewart SL Ovarian Cancer Incidence: Current and Comprehensive Statistics Ferlay J.; Shin H.R.; Bray F.; Forman, D., Mathers, C. & Parkin, D.M. (2008) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; Available from: accessed on 21/07/ Karst AM, Drapkin R. Ovarian Cancer Pathogenesis: A Model in Evolution. Hindawi Publishing Corporation Journal of Oncology Volume 2010, Article ID , 13 pages doi: /2010/ Anonym. Ovarian cancer - UK incidence statistics available from : 5. Berek JS, Friedlander M, Hacker NF. Epithelial ovarian, fallopian tube, and peritoneal cancer Berek and Hacker's Gynecologic Oncology, 4th Edition 6. Aziz MF. Gynecological cancer in Indonesia. J Gynecol Oncol Vol. 20, No. 1:8-10, March 2009 DOI: /jgo Gajjar K, Ogden G, Mujahid MI, Razvi K. Symptoms and Risk Factors of Ovarian Cancer: A Survey in Primary Care. International Scholarly Research Network ISRN Obstetrics and Gynecology Volume 2012, Article ID , 6 pages doi: /2012/ Banks E. The Epidemiology of Ovarian Cancer in Ovarian Cancer Methods and Protocols.vol. 3. Humana press. Totowa,New Jersey.;p 9. Schorge JO et al, Epithelial ovarian cancer in Williams Gynecology, 1 st ed. New York, Mc Graw Hill, 2008,p 716

2 10. Parkin, D. M., Muir, C., Whelan SF., et al., (eds.) (1992) Cancer Incidence in Five Continents.IARC Scientif. Lyon, France 11. Annegers SP, Stromm H, David GD, Decker DD, Dockert MB, O Fallon M,.Incidence and Case-Control Study. Cancer 43: , Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder N,Magnusson CM, Persson IR. Risk Factors for Invasive Epithelial Ovarian Cancer: Results from a Swedish Case- Control Study. American Journal of Epidemiology. Am J Epidemiol Vol. 156, No. 4, p; Hankinson SE, Colditz GA, Hunter D,Willett WC,Sfampfer M,Rosner B,Hennekens CH,Speizer FE. A Prospective Study of Reproductive Factors and Risk of Epithelial Ovarian Cancer. CANCER July 15,1995, Volume 76, No John M. S. Bartlett. Ovarian cancer method and protocols 15. Risch HA, Marret LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Amer. J. Epidemiol. 140, Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Amer. J. Epidemiol. 136, Salehi F, Dunfield L, Phillips KP,Krewski D,Vanderhyden BC. Risk Factors For Ovarian Cancer: An Overview With Emphasis On Hormonal Factors. Journal of Toxicology and Environmental Health, Part B, 11: , Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009; 374:. September 29, Quirk JT, Natarajan N: Ovarian cancer incidence in the United States, Gynecol Oncol 97:519, 2005 [PMID: ]

3 20. Goodman MT, Howe HL, Tung KH, et al: Incidence of ovarian cancer by race and ethnicity in the United States, Cancer 97:2676, 2003 [PMID: ] 21. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol. 2007;25: WHO, GLOBOCAN, International Agency of Research and Cancer, Berek JS, Hacker NF, Gynecologyc Oncology in chapter 11, Epithelial ovarian cancer, 5th edition, Lippincott William&wilkins, Winter III WE, Maxwel GL, Tian C, Carlson JW, Ozol RFs, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP.Prognostic Factors for Stage III Epithelial 25. Hess V, A Hern R, Nasiri N, et al: Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment. J Clin Oncol 22: , Zorn KK, Awtrey CS, Gardner GJ, et al: Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Gynecol Oncol 88:A90, Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am J Surg Pathol. 2000;24: Levine DA,De Los Santos J,Fleming G, Barakat RR,Markman M, Randal ME. Ovarian cancer in Handbook for principles and practice of gynecologic oncology.lipincot williams wilkin.2010; p: van Altena AM, Karim-Kos KE, de Vries E, Kruitwagen RFPM,Massuger LFAG, Kiemeney LA. Trends in therapy and survival of advanced stage epithelial ovarian

4 cancer patients in the Netherlands. Gynecologic Oncology 125 (2012) Available from Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20: Gershenson DM, Silva EG, Mitchell MF, et al: Transitional cell carcinoma of the ovary: A matched control study of advanced-stage patients treated with cisplatin-based chemotherapy. Am J Obstet Gynecol 168:1178, Busmar B. Kanker ovarium dalam Buku Acuan Nasional Onkologi Ginekologi,edisi I. Yayasan bina pustaka sarwono prawirohardjo,2006 ;hal Rustin GJS, van der Burg MEL, Berek JS. Tumor markers. Ann Oncol 1993;4:S71- S Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 2002;85: Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Fujibayashi Y, Yonekura Y, et al. Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range. Ann Nucl Med 2002;16: Jung SE, Lee JM, Rha SE, Byun JY, Jung JI, Hahn ST. CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics 2002;22: Eisenhauera EA, Therasseb P,Bogaertsc J,Schwartzd LH.Sargente D,Fordf R, Danceyg J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). EUROPEAN JOURNAL OF CANCER 45 (2009)

5 38. Gordon J. Rustin S. Can We Now Agree to Use the Same Definition to Measure Response According to CA-125?. Journal of Clinical Oncology, Vol 22, No 20 (October 15), 2004: pp Available from : O Malley CD,. Cress RD, Campleman SL, Leiserowitz GS. Survival of Californian women with epithelial ovarian cancer, : a population-based study. Gynecologic Oncology 91 (2003) Marszalek A, Alran S, Scholl S, Fourchotte V, Plancher C, Rosty C, Meyniel JP, VD Margerie, Dorval T, Rochefordi`ere A De La, Cottu P, Petrow P, SastreGarrau X, Salmon RJ. Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute. Hindawi Publishing Corporation International Journal of Surgical Oncology Volume 2010, Article ID Iyoke CA, Ifeadike CO, Nnebue CC, Nkwo PO, Ezugwu EC, Edosuyi L, Onah LN,Onah HE, Okafor O.A Ten-Year Review of Ovarian Cancer in Enugu, South East Nigeria. Afrimedic Journal 2011;2(1): Whiteman DC,Murphy MFG, Cook LS,Cramer DW, Hartge P, Marchbank PAs, Nasca PC, Ness RB, Purdie DM,Risch HA Multiple Births and Risk of Epithelial Ovarian Cancer. Journal of the National Cancer Institute, Vol. 92, No. 14, July 19, Green GE,. Mortele KJ, Glickman JN, Benson CB. Brenner Tumors of the OvarySonographic and Computed Tomographic Imaging Features. J Ultrasound Med 2006; 25: Duska LR, Chang YC, Flynn CE, Chen AH, Goodman A, Fuller AF, Nikrui N.Epithelial Ovarian Carcinoma in the Reproductive Age Group. Cancer June 15,1999/volume 85 / Number 12